Shilpa Medicare Limited (SHILPAMED.NS)
INR 630.45
(-2.57%)
INR 630.45
(-2.57%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.33 Billion INR | -65.24% |
| 2022 | 6.27 Billion INR | -0.43% |
| 2021 | 6.3 Billion INR | 23.53% |
| 2020 | 5.1 Billion INR | 13.73% |
| 2019 | 4.48 Billion INR | 37.18% |
| 2018 | 3.26 Billion INR | 17.48% |
| 2017 | 2.78 Billion INR | 27.34% |
| 2016 | 2.18 Billion INR | 54.38% |
| 2015 | 1.41 Billion INR | -7.43% |
| 2014 | 1.52 Billion INR | 14.51% |
| 2013 | 1.33 Billion INR | 30.23% |
| 2012 | 1.02 Billion INR | 22.05% |
| 2011 | 840.27 Million INR | 43.23% |
| 2010 | 586.64 Million INR | 10.42% |
| 2009 | 531.28 Million INR | 24.63% |
| 2008 | 426.29 Million INR | 283.37% |
| 2007 | 111.19 Million INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 539.63 Million INR | -7.12% |
| 2023 Q1 | 1.51 Billion INR | -6.46% |
| 2023 Q4 | 580.96 Million INR | -61.46% |
| 2023 Q3 | 1.5 Billion INR | -2.56% |
| 2023 Q2 | 1.54 Billion INR | 2.35% |
| 2023 FY | 2.18 Billion INR | -65.24% |
| 2022 Q3 | 1.49 Billion INR | -4.95% |
| 2022 FY | 6.27 Billion INR | -0.43% |
| 2022 Q1 | 1.59 Billion INR | -5.05% |
| 2022 Q4 | 1.61 Billion INR | 7.87% |
| 2022 Q2 | 1.57 Billion INR | -0.93% |
| 2021 Q1 | 1.47 Billion INR | -10.86% |
| 2021 FY | 6.3 Billion INR | 23.53% |
| 2021 Q4 | 1.67 Billion INR | 7.08% |
| 2021 Q3 | 1.56 Billion INR | -1.63% |
| 2021 Q2 | 1.59 Billion INR | 8.07% |
| 2020 Q4 | 1.65 Billion INR | 37.02% |
| 2020 FY | 5.1 Billion INR | 13.73% |
| 2020 Q2 | 1.19 Billion INR | 13.35% |
| 2020 Q3 | 1.2 Billion INR | 1.0% |
| 2020 Q1 | 1.05 Billion INR | -1.8% |
| 2019 Q3 | 1.1 Billion INR | -21.42% |
| 2019 FY | 4.48 Billion INR | 37.18% |
| 2019 Q1 | 890.48 Million INR | 44.09% |
| 2019 Q2 | 1.4 Billion INR | 57.66% |
| 2019 Q4 | 1.07 Billion INR | -2.85% |
| 2018 Q3 | 923.84 Million INR | 3.14% |
| 2018 Q1 | 831.8 Million INR | -8.11% |
| 2018 FY | 3.26 Billion INR | 17.48% |
| 2018 Q2 | 895.68 Million INR | 7.68% |
| 2018 Q4 | 618 Million INR | -33.11% |
| 2017 FY | 2.78 Billion INR | 27.34% |
| 2017 Q2 | 712.23 Million INR | 8.08% |
| 2017 Q1 | 658.97 Million INR | -16.2% |
| 2017 Q4 | 905.2 Million INR | 18.76% |
| 2017 Q3 | 762.22 Million INR | 7.02% |
| 2016 Q1 | 545.78 Million INR | -8.6% |
| 2016 Q4 | 786.34 Million INR | 15.23% |
| 2016 Q3 | 682.43 Million INR | 13.41% |
| 2016 Q2 | 601.71 Million INR | 10.25% |
| 2016 FY | 2.18 Billion INR | 54.38% |
| 2015 FY | 1.41 Billion INR | -7.43% |
| 2015 Q1 | 455.68 Million INR | 78.94% |
| 2015 Q2 | 547.56 Million INR | 20.16% |
| 2015 Q3 | 586.33 Million INR | 7.08% |
| 2015 Q4 | 597.11 Million INR | 1.84% |
| 2014 Q4 | 254.65 Million INR | -42.85% |
| 2014 FY | 1.52 Billion INR | 14.51% |
| 2014 Q1 | 394.97 Million INR | 353.7% |
| 2014 Q2 | 434.01 Million INR | 9.88% |
| 2014 Q3 | 445.61 Million INR | 2.67% |
| 2013 Q2 | 440.45 Million INR | 10.4% |
| 2013 FY | 1.33 Billion INR | 30.23% |
| 2013 Q4 | 87.05 Million INR | -78.72% |
| 2013 Q3 | 409.06 Million INR | -7.13% |
| 2013 Q1 | 398.96 Million INR | 51.38% |
| 2012 Q1 | 270.26 Million INR | 50.79% |
| 2012 Q3 | 273.29 Million INR | 34.12% |
| 2012 Q4 | 263.54 Million INR | -3.57% |
| 2012 Q2 | 203.77 Million INR | -24.6% |
| 2012 FY | 1.02 Billion INR | 22.05% |
| 2011 Q2 | 210.37 Million INR | 20.55% |
| 2011 Q1 | 174.52 Million INR | 0.0% |
| 2011 FY | 840.27 Million INR | 43.23% |
| 2011 Q4 | 179.22 Million INR | -30.4% |
| 2011 Q3 | 257.51 Million INR | 22.41% |
| 2010 FY | 586.64 Million INR | 10.42% |
| 2009 FY | 531.28 Million INR | 24.63% |
| 2008 FY | 426.29 Million INR | 283.37% |
| 2007 FY | 111.19 Million INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Sigachi Industries Limited | 579.88 Million INR | -474.97% |
| Ind-Swift Limited | 946.56 Million INR | -252.239% |
| Innova Captab Limited | 931.03 Million INR | -258.117% |
| Aarti Drugs Limited | 1.16 Billion INR | -185.588% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -8.45% |
| Bajaj HealthCare Limited | 985.34 Million INR | -238.377% |
| Sakar Healthcare Limited | 204.07 Million INR | -1533.768% |
| Aurobindo Pharma Limited | 55.65 Billion INR | 94.01% |
| Solara Active Pharma Sciences Limited | 2.55 Billion INR | -30.542% |
| AstraZeneca Pharma India Limited | 2.47 Billion INR | -34.796% |
| Mangalam Drugs & Organics Limited | 162.22 Million INR | -1955.241% |
| Morepen Laboratories Limited | 1.98 Billion INR | -67.762% |
| Sequent Scientific Limited | 2.9 Billion INR | -14.9% |
| Wanbury Limited | 978.96 Million INR | -240.581% |
| Laurus Labs Limited | 11.9 Billion INR | 72.005% |
| Nectar Lifesciences Limited | 932.7 Million INR | -257.476% |
| Gufic Biosciences Limited | 1.18 Billion INR | -180.988% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | 71.358% |
| Alembic Limited | 872.45 Million INR | -282.159% |
| Hikal Limited | 4.46 Billion INR | 25.306% |
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | 78.99% |
| Glenmark Pharmaceuticals Limited | 46.95 Billion INR | 92.899% |
| IOL Chemicals and Pharmaceuticals Limited | 2.2 Billion INR | -51.485% |
| Themis Medicare Limited | 1.12 Billion INR | -196.161% |
| RPG Life Sciences Limited | 1.63 Billion INR | -103.863% |
| Lupin Limited | 125.09 Billion INR | 97.335% |
| Amrutanjan Health Care Limited | 2.09 Billion INR | -59.222% |
| Wockhardt Limited | 8.48 Billion INR | 60.682% |
| Vaishali Pharma Limited | 84.02 Million INR | -3867.888% |
| Jagsonpal Pharmaceuticals Limited | 438.55 Million INR | -660.273% |
| NATCO Pharma Limited | 10.05 Billion INR | 66.85% |
| Jubilant Pharmova Limited | 14.45 Billion INR | 76.932% |
| FDC Limited | 3.49 Billion INR | 4.731% |
| Divi's Laboratories Limited | 14.17 Billion INR | 76.47% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -708.428% |
| Eris Lifesciences Limited | 4.94 Billion INR | 32.547% |
| Windlas Biotech Limited | 1 Billion INR | -231.261% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 97.838% |
| Mankind Pharma Limited | 29.27 Billion INR | 88.61% |
| Venus Remedies Limited | 1.91 Billion INR | -73.992% |
| ZIM Laboratories Limited | 1.01 Billion INR | -229.12% |
| Neuland Laboratories Limited | 2.92 Billion INR | -13.804% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.79 Billion INR | 77.46% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -210.391% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 97.337% |
| Bal Pharma Limited | 555.62 Million INR | -500.076% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 96.522% |
| Par Drugs and Chemicals Limited | 58.28 Million INR | -5620.176% |
| Caplin Point Laboratories Limited | 2.17 Billion INR | -53.331% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -134.93% |
| Orchid Pharma Limited | 800.77 Million INR | -316.371% |
| Albert David Limited | 1.02 Billion INR | -224.922% |
| Ajanta Pharma Limited | 30.46 Billion INR | 89.055% |
| Hester Biosciences Limited | 908.84 Million INR | -266.861% |
| Valiant Laboratories Limited | 138.02 Million INR | -2315.563% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -137.682% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -11.31% |
| Aarey Drugs & Pharmaceuticals Limited | 14.21 Million INR | -23358.643% |
| Granules India Limited | 10.31 Billion INR | 67.67% |
| Alkem Laboratories Limited | 32.83 Billion INR | 89.846% |
| Medicamen Biotech Limited | 335.16 Million INR | -894.781% |
| Unichem Laboratories Limited | 6.72 Billion INR | 50.428% |
| Bafna Pharmaceuticals Limited | 455.58 Million INR | -631.845% |
| Biofil Chemicals and Pharmaceuticals Limited | 6.82 Million INR | -48788.226% |
| Medico Remedies Limited | 59.67 Million INR | -5487.226% |
| Ipca Laboratories Limited | 18.98 Billion INR | 82.44% |
| Syncom Formulations (India) Limited | 345.63 Million INR | -864.658% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -56.963% |
| Brooks Laboratories Limited | 51.18 Million INR | -6414.609% |
| Piramal Enterprises Limited | 63.65 Billion INR | 94.762% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | 84.436% |
| Suven Life Sciences Limited | 109.75 Million INR | -2937.974% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -7123.713% |
| Strides Pharma Science Limited | 9.16 Billion INR | 63.61% |
| Indoco Remedies Limited | 12.06 Billion INR | 72.356% |
| Alpa Laboratories Limited | 127.38 Million INR | -2517.504% |
| Lasa Supergenerics Limited | 291.17 Million INR | -1045.081% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -8.365% |